Isolated human Purkinje fibres (PFs) in combination with electrophysiology are a unique tool that can be used to understand subtle differences between drugs on cardiac conduction. Ozanimod is an oral once-daily immunomodulator that has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. The goal was to determine whether the higher selectivity of Ozanimod explains its improved clinical profile. The data agreed that Ozanimod has no effect on the measured conduction parameters.

AUTHORS: Najah Abi-Gerges, Paul E. Miller, Andre Ghetti, Fiona L. Scott, Kristen R. Taylor Meadows, Bryan Clemons, Paul Frohna, Guy Page, Gregory J. Opiteck